Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

ECCMID 2019: new guideline on invasive fungal infections

25/04/2019

A dedicated working group of the European Society of Clinical Microbiology and Infectious Diseases is developing a new guideline on invasive fungal infections, which could be of particular relevance for the ICU population. Despite the guideline still being in an early phase, prof. Cornelia Lass-Flörl, who is actively involved in this new guideline, was eager to share some details on the background, methodology, contents, usefulness and expected timelines of this guideline.    This editorially independent interview has been financially sponsored by Gilead.

  • 00:08:54
 

EMUC 2018: Take home messages

12/12/2018

Dr. Laurence Albiges, medical oncologist at the Institut Gustave Roussy (France), shares with us her take home messages of EMUC 2018, several of which might have practice changing potential. 

  • 00:05:17
 

ASH 2018: Highlights lymphoma

11/12/2018

Dr. Martin Hutchings from Denmark talks about the first in-human trial he presented at ASH 2018 and mentions another congress highlight: the ECHELON-2 trial.

  • 00:04:13
 

ESMO 2018 in depth: Abiraterone plus prednisone in high and low risk metastatic hormone naïve prostate cancer

06/11/2018

Alex Hoyle, oncologist at the Christie and Salford Royal Hospitals in Manchester, provides information on the effects of abiraterone plus prednisone in high and low risk metastatic hormone naïve prostate cancer patients.   

  • 00:02:54
 

Quarterly Focus on Hematology | CLL

10/01/2019

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented. In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL. Guests Prof. Arnon Kater, MD, PhD Hematologist, Amsterdam UMC (AMC), The Netherlands Prof. Stephan Stilgenbauer, MD Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany Gert Jan Timmers, MD, PhD Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands Prof. Paolo Ghia, MD, PhD Internist, Università Vita-Salute San Raffaele, Milan, Italy Kostas Stamatopoulos, MD, PhD CERTH, Thessaloniki, Greece   Publications to be discussed Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018 Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019 About our "Quarterly Focus" format Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

 

Quarterly Focus on GU | Bladder Cancer

21/11/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Michiel van der Heijden, MD, PhD - medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Fred Witjes, MD -  urologist, Radboudumc, Nijmegen Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen Program: Speaker: Prof. Dipen Parekh, MD – urologist at University of Miami Health System in Miami, USA Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial Lancet 391, 2018 Speaker: Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam, The Netherlands Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Lancet 391, 2017

 

Quarterly Hematology: highlights in Hodgkin Lymphoma

11/10/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Two high-impact international publications on Hodgkin Lymphoma of the past year will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The expert panel consists of: Josée Zijlstra, MD, PhD, hematologist, VUmc Amsterdam Wouter Plattel, MD, PhD, hematologist, UMC Groningen Live video guests: HD18: Prof. Peter Borchmann, MD, PhD, hematologist, University Hospital of Cologne, Germany H10: Prof. Massimo Federico, MD, hematologist, University of Modena and Reggio Emilia, Italy

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Congress news 19/11/2019

Highlights of the Trends in Medical Mycology 2019

From October 11th until the 14th, the 9th edition of the Trends in Medical Mycology has been held in Nice, France. Since conferences run parallel sessions, it is impossible to acquire every bit of information. As we still face several difficulties in the management of potential lethal invasive fungal diseases, this might just as well be life saving information. Therefore, MEDtalks traveled to Nice to interview renowned experts to bring you up to speed on developments that impact clinical practice. Speakers & topics Prof. Adilia Warris, MD, PhD Management of invasive fungal infections in paediatrics - what is new? Prof. Paul Verweij, MD, PhD Stewardship and azole resistant aspergillosis: a challenge for farmer or physician? Bart Rijnders, MD, PhD Aspergillus in the ICU: influenza-associated aspergillosis Anna Skiada, MD, PhD Management of mucormycosis - what is new?

Congress news 19/11/2019

TIMM 2019: azole resistant invasive aspergillosis

One of the major challenges in the management of invasive aspergillosis is resistance against azoles. For this reason, prof. Paul Verweij, MD, PhD, expands on this subject. He will share details on the current epidemiology of azole resistance and explains how antifungal stewardship can help to control the increase of resistance.

Congress news 19/11/2019

TIMM 2019: paediatric invasive fungal infections

Chairwoman prof. Adilia Warris, MD, PhD, elaborates on the goals of the European Peadiatric Mycology Network to improve the management of invasive fungal infections. Furthermore, she shares new insights on epidemiology, diagnostic tests and treatment of invasive fungal infections in children.

Congress news 19/11/2019

TIMM 2019: mucormycosis

Anna Skiada, MD, PhD brings you up to speed on the developments on management of mucormycosis, like recent guideline updates. Also, she talks about the importance of registries for mucormycosis to get more knowledge about this potential lethal disease.

Congress news 19/11/2019

TIMM 2019: influenza-associated aspergillosis

Influenza-associated aspergillosis is a difficult problem for critically ill ICU patients. Bart Rijnders, MD, PhD, was eager to share some insights on epidemiology, etiology and management of influenza-associated aspergillosis. Moreover he elaborates on endeavors to improve outcome for these patients (e.g. research and the development of guidelines).

Congress news 10/10/2019

ESMO 2019 Osimertinib as first-line treatment for NSCLC: final OS analysis

The FLAURA-studie compares the effectivity of the EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib to the EGFR-TKI's gefitinib of erlotinib in NSCLC. In 2018, benefit in progression-free survival was reported for osimertinib. At this ESMO congress, dr. Suresh Ramalingam (Winship Cancer Institute of Emory University), presented the results on overall survival.

Congress news 10/10/2019

ESMO 2019 Veliparib with carboplatin and paclitaxel in HER2-negative breast cancer

At this ESMO congress, medical oncologist Véronique Diéras presented a late breaking abstract on the BROCADE-3 trial. In this trial the effectivity and tolerability of veliparib with chemotherapy was investigated in patients with BRCA-positive HER2-negatieve breast cancer. In this interview, Dr. Diéras summarizes the main findings.

Congress news 08/10/2019

ESMO 2019 Analysis of tumor hyperprogression with nivolumab in RCTs

Pulmonologist prof. Martin Reck from the LungenClinic Großhansdorf in Germany presented results on a relatively new phenomenon: tumor hyperprogression after treatment with immunotherapy. In the CheckMate 451 cohort, the occurence of this phenomenon with nivolumab-treated es-SCLC patients was evaluated.